Sebaceous gland nicotinic acetylcholine receptor alpha7 (nAChRα7)

Sebaceous glands synthesize and secrete sebum, contributing to skin barrier and homeostasis. Recent research demonstrates that human sebocytes and sebaceous glands express nicotinic acetylcholine receptor alpha7 (nAChRα7), which mediates the effect of acetylcholine on lipid synthesis. Stimulation of this receptor increases sebum production, while antagonism (e.g., by α-bungarotoxin) blocks this response. Pharmacologic inhibition of acetylcholine release by botulinum toxin reduces sebum output, indicating clinical relevance for disorders of sebaceous gland hyperactivity such as acne vulgaris. Cholinergic pathways thus represent a promising therapeutic target for managing sebum-related disorders[1][3][6].

Other names

Nicotinic acetylcholine receptor alpha7nAChRα7α7-nAChRAcetylcholine receptor, nicotinic, alpha7 subunit (for sebaceous gland context)

Agonists (e.g., acetylcholine, nicotine) increase lipid synthesis in sebocytes via nAChRα7[1][3]. Antagonists (e.g., α-bungarotoxin) block this effect[1]. Botulinum toxin blocks acetylcholine release in nerves, thereby reducing sebaceous gland activity[1].